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Introduction
Elsewhere in this issue, Frei and co-workers report
that the number of antihypertensive drugs needed to
control blood pressure in 639 kidney allograft recipi-
ents was one of the most significant predictors of
chronic progressive renal allograft dysfunction as
defined by a 1/creatinine slope of >0.1 dl/mg/year [1].
Surprisingly this was not only true at 1 year after
transplantation (where hypertension might be assumed
to result from subclinical rejection or CsA toxicity),
but also before transplantation. Antihypertensive ther-
apy before transplantation was a much more important
predictor than the degree of HLA matching and second
only to the presence or absence of acute rejections.
Although the study does not address the mechanisms
by which pretransplant hypertension could impair
long-term graft function, it raises the hypothesis that
the recipient's cardiovascular risk profile has a pro-
found effect on the transplanted kidney. This should
prompt a reconsideration of non-immunological
factors in chronic allograft rejection.
Morphology of chronic transplant rejection
The histological hallmarks of chronic rejection are
fairly uniform in transplanted kidneys, livers, and
hearts. They consist of arterial intimal thickening, for
which the term 'fibroproliferative endarteritis' has
been coined, and a persistent low-grade perivascular
inflammatory infiltrate. Although these changes in
some respects resemble 'simple' atherosclerosis, they
may be differentiated by being both concentric (rather
than eccentric) and generalized (rather than segmen-
tal). In the kidney these changes are accompanied by
proliferative and sclerotic lesions of the glomeruli, by
interstitial fibrosis, and by tubular atrophy.
Endothelial damage appears to be an early key event
in both atherosclerosis and transplant vasculopathy,
leading to attachment and penetration of mononuclear
cells into the vascular intima whose proliferation may
then be stimulated by a variety of growth factors
(PDGF, TGF-/?), vasoactive hormones (endothelin)
and cytokines (IL-6). Once altered in this way, the
vascular intima may become susceptible to the common
atherogenic factors like hypertension and hyperlipidae-
mia. The increasing role of non-immunological factors
after the initial insult is highlighted by attempts to
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reverse the immunological component experimentally:
retransplantation of an organ back to the original
donor fails to reverse or stop the process if a critical
time period has elapsed [2]. Consistent with this,
fibroproliferative endarteritis is observed in long-term
rat isografts as well as allografts, although it develops
more rapidly in the latter [3].
Association of hypertension and progressive loss of
renal graft function
Arterial hypertension, which occurs in some 50% of
all renal transplant patients, is associated with
decreased rates of graft survival and—consistent with
the study of Frei et al.—with more rapid declines of
GFR beyond the first year [4]. Commonly identified
causes of post-transplant hypertension include pressor
effects of the native kidneys, rejection, CsA therapy,
and impaired GFR.
Since high blood pressure might be both the result
and a causative factor of the destructive process, one
would be grateful for a prospective study demonstrat-
ing the use of antihypertensive therapy. Unfortunately
there is none, and the available retrospective evidence
is equivocal. For example, in a study of 144 kidney
transplant recipients, Cheigh and co-workers found no
difference in graft survival between patients with con-
trolled versus uncontrolled hypertension [5], although
hypertension per se significantly impaired 10-year graft
survival. In contrast, a study of 135 patients with grafts
functioning at 1 year found that hypertensive patients
did significantly better if their blood pressure was
medically controlled [6].
Mechanisms by which hypertension may mediate
graft loss
Beyond the 'atherogenic' effect on arteries and arteri-
oles, hypertension may cause glomerular damage, if
the systemic level of blood pressure is transmitted to
the glomerulus. Grafts undergoing chronic rejection
usually carry the stigmata of the hypertrophy-*
glomerulosclerosis pathway [7] as established by the
studies of Brenner and others. Brenner recently
advanced the concept that transplants are doomed to
failure if the number of transplanted nephrons fails to
match the recipient's requirements, resulting in hyper-
filtration at the price of an increased glomerular pres-
sure [8]. In the view established by Arthur Guyton,
an insufficient number of nephrons would shift the
pressure-natriuresis curve to the right, and hyperten-
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sion would develop because salt balance may only be
achieved at increased blood pressure.
A mere 50% reduction of renal mass does not appear
sufficient to initate the vicious circle of hyperfiltration
in humans, since humans uninephrectomized in adult-
hood consistently do well for long periods of time. In
contrast, a single transplanted kidney may have an
insufficient number of nephrons, if its mass is further
diminished by rejection or CsA toxicity, or if there is
a size mismatch with the recipient. Terasaki and
co-workers have suggested that many graft failures
labelled as 'rejection' may actually be 'hyperfiltration
failures'. In the large UNOS registry, the following
five situations are both associated with decreased graft
survival and are likely to go along with hyperfiltration
[9]: (1) transplantation of kidneys from small
donors (ages 4-6) into adults; (2) transplantation into
recipients > 100 kg; (3) transplantation of kidneys from
females into males; (4) kidneys undergoing rejection
episodes; and (5) cadaver kidneys in general relative
to living donor kidneys.
Other non-immunological mechanisms in chronic
graft rejection
Serum cholesterol appears to be an independent risk
factor for transplant coronary vasculopathy in heart-
transplant recipients [10], and elevated levels of LDL
cholesterol were found to have a significant negative
effect on 4-year kidney graft survival in 98 Finnish
transplant recipients [11]. Interventional studies in
kidney transplants are not available, but recent, prelim-
inary data in heart-transplant recipients suggest that
lowering serum cholesterol by pravastatin is able to
decrease transplant coronary disease [12]. Among
other common 'atherogenic' factors, smoking has not
been found to be associated with an increased risk of
chronic graft failure. The situation is similar with
obesity: although a recipient weight > 100 kg was asso-
ciated with an impaired 1- and 3-year graft survival in
the UNOS registry, the difference did not appear to
increase beyond the first year as one would expect if
chronic rejection were favoured by obesity [9], and
other authors found that obesity did not constitute a
major risk for 3-year survival.
Pre-transplant hypertension and graft outcome
Although mysterious at first glance, there are several
possibilities as to how pre-transplant hypertension
might impair graft prognosis. First there is a close
correlation of pre-transplant with post-transplant
hypertension such that the same factors which render
antihypertensive treatment difficult prior to trans-
plantation (such as obesity, poor compliance, high
NaCl intake, pressor effects of the native kidneys) are
expected to operate after transplantation as well.
Second, pre-transplant hypertensive patients may have
adapted to a higher blood pressure for a long time and
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their hypertension may therefore be harder to control
after transplantation. Third, pre-transplant hyper-
tension may be associated with a general propensity
for atherosclerosis and hypercholesterolaemia and
thus represent a risk indicator for the time after
transplantation.
Consequences for patient management
As outlined, accumulating data suggest that hyperten-
sion and hypercholesterolaemia adversely affect the
long-term fate of the transplanted kidney, but conclus-
ive evidence for a protective effect of lowering blood
pressure and cholesterol on chronic graft rejection is
missing. The puzzling finding by Frei et al. that pre-
transplantation hypertension is somehow connected
with long-term graft function may lead one to suspect
a negative effect of the native kidneys and to consider
their removal. Predicting the success of this manoeuvre
has, however, been exceedingly difficult and the mor-
bidity not trivial. With today's antihypertensive drugs
it should be possible to reach an acceptable level of
blood pressure control in virtually every renal trans-
plant patient. The ideal level, however, is entirely
speculative. The similarity of chronic graft rejection
with non-immunological progression of renal failure
suggests that simple 'normalization' of pressure may
not be enough and that 120/80 may be better than
140/90 [13]. To diminish glomerular hypertension and
hyperfiltration, a decrease of GFR may be unavoid-
able, and medications currently promoted for their
'kidney sparing' effects may prove to be non-protective
for that very reason.
Normalization of blood pressure and lipids has
become standard medical management and is under-
taken for reasons other than the prevention of chronic
graft failure. We do, however, need studies which tell
us what level of blood pressure we should target and
which antihypertensive drugs are suitable. Meanwhile
it may be wise to treat our patients' hypertension as
aggressively after transplantation as we do before.
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Editor's note
Please see also the Original Article by U. Frei (pp. 1206-1211 in
this issue).
When dialysis becomes worse than death
A. Sessa
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Dialysis has become a readily accessible form of life-
sustaining treatment. The criteria for accepting patients
into chronic programmes have become less restrictive
and today disabled patients, elderly patients, and
patients with accompanying diseases are admitted for
renal replacement therapy. In fact the continuous
increase in the number of dialysis patients is explained
by, amongst other factors, increasing acceptance of
patients with poor prognosis [1,2]. Recent analyses of
the causes of death in patients on dialysis revealed
that, after cardiac events and infectious disease, with-
drawal from dialysis is the third most common cause
of death in the United States [3]. It is possible that
withdrawal might become even more common in the
future, as the number of disabled patients taken on
chronic dialysis increases progressively.
The decision of a mentally competent patient to
discontinue dialysis is now generally accepted in the
US and the right of a patient to refuse life-prolong-
ing treatment has clearly been established [4]. The
American Medical Association has denned specific
guidelines for physicians concerning the ethical and
legal aspects of withdrawing life-sustaining treatments
[5]; life-sustaining treatment is denned as any treatment
useful to prolong life without reversing the underlying
medical condition.
Physicians are obliged to promote the dignity and
the autonomy of dying patients. The principle of
patient autonomy implies that physicians must respect
the decision to refuse life-sustaining treatment of a
competent patient. The obligation to offer specific
treatment for a specific disease therefore does not
include an obligation to impose or to continue treat-
ment on an 'unwilling' patient who has the freedom
Correspondence and offprint requests to: Prof. A. Sessa, Unita
Operativa di Nefrologia e Dialisi, Via C. Battisti 23, Ospedale di
Vimercate, 1-20059 Vimercate, Italy.
to make his choice in accordance with his own values
[6,7]. The physician is obliged only to offer treatment
to relieve distressing symptoms, respecting the prin-
ciples of 'non-maleficience' and of 'beneficience' for
the patients [5].
I wish to argue that the crucial question facing
physicians is whether or not 'to permit' patients to
discontinue dialysis; it is essential that nephrologists
have well-defined guidelines to review appropriately
with the patient all circumstances and problems that
might have led to the decision to discontinue medical
care, because the patient feels it is no longer beneficial;
the aim should be to modify the patient's decision.
Evaluation and discussion between patient and
nephrologist should include a complete review of the
clinical circumstances, e.g. sources of pain, non-
medical approaches to reduce suffering, poverty, loneli-
ness, and loss of social role, prospects of transplanta-
tion, psychiatric treatment of depression etc. [8]. In
fact, it is an illusion to think that patients do not suffer
in the process of withdrawing from treatment and
dying [9]. Nevertheless, patients become increasingly
concerned that the dying process is needlessly pro-
tracted by biomedical technology, involving poor qual-
ity of life, intolerable pain, and loss of human dignity.
Prominent reasons given by patients for their
decision to discontinue chronic dialysis treatment are
dissatisfaction with life style, advancing age, with ser-
ious medical problems, physical impairment, neurolog-
ical disability, severe pain, financial consequences of
treatment, etc.
There has been a change in the 'culture' of dying.
Until the recent past, sick people were treated at home,
and usually patients also died at home. Today, how-
ever, the vast majority of deaths occur in medical
institutions, laying the burden of ethical and legal
responsibilities on the shoulders of physicians. In the
